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Primary primitive neuroectodermal tumor (PNET) of the ovary is
a rare entity. PNETs may be classiﬁed under 2 broad categories with
differing clinical characteristics, immunohistochemical proﬁles and
genetics: (i) central PNET (cPNET) and (ii) peripheral PNET (pPNET).
PNETs in general are aggressive cancers associatedwith a highmortality
(Kovar, 1998). We present a case of a patient diagnosed with cPNET
arising from a mature cystic teratoma during pregnancy, managed
with fertility-preserving surgery.
Case report
A 27 year old nulliparous Chinesewoman presented to her obstetri-
cian at 12 weeks of gestation. Ultrasound showed a left triloculated cyst
measuring 8.9×7 cmand serum tumormarkers (CA-125, CEA and AFP)
were normal. She underwent an open ovarian cystectomy at 14 weeks
of gestation in June 2009. Therewas an iatrogenic capsular rupture dur-
ing the cystectomy.
Gross examination of the resected ovarian cyst revealed locules
containing sebaceous material and hairs (Fig. 1). The largest locule
showed a mural nodule measuring 8×5×3 cm, with adipose, cartilagi-
nous and bony areas. Histological examination of the ovarian cyst⁎ Corresponding author.
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testinal tract, respiratory tract, cartilage, lamellar bone, hematopoietic
and neural tissue (Fig. 2). However, the mural nodule from the largest
locule showed an area of malignant transformation, comprising a nod-
ular focus of PNET measuring 7 mm in greatest dimension (Fig. 3A).
The PNET was composed of sheets of primitive round cells with high
nuclear-cytoplasmic ratio, frequent mitoses and focal necrosis, set in a
ﬁnely ﬁbrillary background (Fig. 3B and C). At its edges, the PNET
showed inﬁltration into surroundingmature teratomatousneural tissue
(Fig. 3D). Several adjacent foci of lymphovascular invasionwere also seen
(Fig. 3E). Immunohistochemical studies demonstrated within the PNET
expression of neural markers chromogranin A and synaptophysin, and a
Ki67 labeling index of 90% (Fig. 3B). There was absence of immunoreac-
tivity for CD99, indicating that the tumor was a central-type PNET.
Chest X-ray (abdominal shielding) andMRI of the abdomen and pel-
vis did not reveal any distantmetastases. She had at least a FIGOStage IC
cPNET of the ovary (T1c NX M0). Subsequently, she was managed by a
multidisciplinary team comprising of a gynecologic oncologist, a medi-
cal oncologist, as well as a maternal fetal medicine specialist.
In viewof the lymphovascular space invasion andhigh risk ofmetas-
tases, coupled with the highly aggressive nature of cPNET, the patient
was counseled for staging surgery and the pros and cons of chemother-
apy were also discussed. However, she declined further surgery and
chemotherapy during pregnancy. Shewas followed up closely through-
out pregnancy, which remained largely uneventful. She delivered a
healthy baby boy at 37 weeks of gestation via an elective lower seg-
ment cesarean section (LSCS), with a birth weight of 2925 g. At the
same time, she underwent a left salpingo-oophorectomy, left pelvic
lymph node sampling, omentectomy and peritoneal washing for stag-
ing. She had opted for a fertility sparing surgery instead of a full staging
surgery. Intra-operatively, the left ovary was slightly nodular, but the
right ovary appeared normal. There was no enlarged retroperitoneal
lymphadenopathy or peritoneal disease. Histological examination of
the remnant left ovary did not show any residual disease, and the left
pelvic lymph nodes, omentum and peritoneal washing were all nega-
tive for malignancy. The patient was then counseled for adjuvant che-
motherapy after her delivery in view of the aggressive nature of
cPNET and evidence of lymphovascular invasion on histology. However,
she declined any further treatment, and was given regular follow-up in
the gynecologic oncology clinic.
Fig. 1. Gross specimen of resected ovarian cyst.
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child in July 2010. She was well antenatally. She delivered her second
child by elective LSCS, with a birth weight of 3438 g. She continued
to be on regular follow up in our hospital, with no cancer relapse
2.5 years after her diagnosis.Fig. 2. Histological diagnosis of mature cystic teratoma. The main tumor was a mature
cystic teratoma, with skin and adipose tissue elements shown here (H&E, low power).Discussion
The incidence of ovarian cysts during pregnancy varies from 1 in
100 to 1 in 2000 pregnancies and malignant ovarian tumors are rela-
tively uncommon.
The primary diagnostic challenge in this case involved dis-
tinguishing between an immature teratoma with only a minor focus
of immature neuroepithelial elements, versus a mature teratoma
with focal secondary malignant (PNET) transformation. The risk of
malignant transformation develops in about 0.17 to 2% of mature
cystic teratomas, and occurs most often in postmenopausal women
(Hinshaw et al., 2012). Malignant neural tumors arising in mature
cystic teratomas are rare, and those reported in young women usually
but not always represent immature teratomas that characteristically
contain immature neuroepithelial elements. Nonetheless, in this
case, the following features indicated the diagnosis of mature cystic
teratoma with secondary malignant (PNET) transformation, i.e. the
nodular focus of primitive round cells arising from the cystic teratoma
did not resemble normal embryonal neural tissue, but instead displayed
anaplastic features consistent with PNET, such as nuclear atypia, a high
mitotic rate and Ki67 labeling index, necrosis, inﬁltrative edges and
lymphovascular invasion. Having established the diagnosis of PNET
arising in amature teratoma,we further performed immunohistochem-
istry for CD99 to distinguish between cPNET and pPNET. Though histo-
logically similar, cPNET and pPNET are different clinical entities, with
different localizations, immunohistochemical proﬁles and genetics
(Morovic and Damjanov, 2008b), and are often confused or not differ-
entiated by authors. cPNET is an embryonal tumor deriving from the
central nervous system (CNS), whereas pPNET arises outside the CNS
and is grouped under the Ewing sarcoma family of tumors. pPNET ex-
presses MIC2 glycoprotein (CD99) and shows the speciﬁc chimeric
gene EWS-FLI1, which can be detected by immunohistochemical
staining for CD99 (Ishii et al., 2001). Often, distinguishing between
cPNET and pPNET is uncomplicated due to the location of the tumor.
However, in this case, the origin of the PNETwithin the ovarian teratoma
necessitated the performance of CD99 immunohistochemistry, and the
negative staining result conﬁrmed a cPNET. This is consistent with ﬁnd-
ings from previous studies that demonstrate that the majority of PNET
transformed from testicular or ovarian germ cell tumors exhibit mor-
phological features of central rather than peripheral PNETs (Ulbright et
al., 2010).
The rarity of cPNET of the ovary precludes randomized clinical study
to guide the management of this disease hence the optimal treatment
strategies have not been established. In general, ovarian PNET malig-
nancies are highly aggressive and the prognosis is poor especially in
the presence of extra-ovarian spread. One of the largest studies by
Morovic and Damjanov (2008a) identiﬁed that disease stage appears
to be themost important prognostic factor in PNET of the ovary. Thema-
jority of patients with Stage I disease (nine out of eleven cases) were
alive and free of disease at a follow-up period of between three to ﬁve
years.Many of the patientswith Stage IA diseasewere treatedwith stag-
ing laparotomy, total hysterectomy bilateral salpingo-ophorectomy,
omentectomy and pelvic/para-aortic lymphadenectomy only, whereas
the Stage IC patients received chemotherapy in addition to surgery. On
the other hand, women with Stage III or IV disease were often treated
with surgery in combination with chemotherapy and or radiotherapy.
Despite treatments, the prognoses of these women with advanced dis-
ease remained poor, the diseases were highly aggressive and rapidly
gave rise to metastases and death.
Fertility-preserving surgery followed by chemotherapy for early
stage PNET of the ovary with successful pregnancies has been reported
recently by Demirtas et al. (2004). He reported a young patient with
Stage IC PNET of the ovary who was treated with unilateral salpingo-
oophorectomy, wedge resection of the right ovary and complete pelvic
and para-aortic lymphadenectomy. She received adjuvant chemothera-
py consisting of bleomycin, etoposide and cisplatin (BEP protocol). Her
Fig. 3. (A) Nodular focus of PNET arising in the mature cystic teratoma (H&E, low power). (B) Immunohistochemistry showed a very high Ki67 labeling index of approximately 90%.
(C) Anaplasia and necrosis, indicative of PNET (H&E, medium power). (D) At its edges, the PNET inﬁltrated adjacent mature teratomatous neural tissue (H&E, medium power). (E) The
PNET showed peritumoral lymphovascular invasion (H&E, medium power).
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tocol was administered. Seven months later, the patient was pregnant
and delivered a healthy baby girl at term. Sixteen months later, the
patient again delivered a healthy infant. However, the two studies by
Morovic and Damjanov (2008a), and Demirtas et al. (2004) described
patients with primary PNET of the ovary and not patients with malig-
nant transformation to PNET within a mature cystic teratoma, which
is the case here.
The optimal chemotherapy regimen for the treatment of cPNET
transformed from germ cell tumors of ovary remains unknown. Man-
agement of these cases is based on case reports and largely extrapolated
from our knowledge of the transformed male germ cell testicular
tumors. For PNETs that are transformed from germ cell tumors, some
authors advocate the use of cisplatin-based chemotherapy, such as
BEP (Bleomycin, Etoposide and Cisplatin), directed at the germ cell
tumors (Demirtas et al., 2004); many other authors however felt that
despite arising within germ cell tumors, PNETs are usually resistant to
cisplatin-based treatment (Ganjoo et al., 2001) and therefore advocate
chemotherapy regimens comprising of doxorubicin, ifosfamide and
cyclophosphamide, directed at the transformed PNET component
(Kleinman et al., 1993; Ehrlich et al., 2010). In one of the largest series
by Ehrlich Y and colleagues, CAV/IE (Cyclophosphamide/Doxorubicin/Vincristine alternating with Ifosfamide/Etoposide), was the treatment
of choice for PNETs transformed from testicular teratoma (Ehrlich et
al., 2010). Yet other authors had used integrated chemotherapy regi-
mens that target both PNET and germ cell tumor (Al-Jumaily et al.,
2012).
In our case, the patientwas diagnosed after an ovarian cystectomy at
14 weeks of gestation. Conventionally, a staging laparotomy followed
by adjuvant chemotherapy would have been performed during preg-
nancy. However, the patient declined and in spite of her reluctance to
undergo any form of adjuvant treatment during pregnancy or even
after delivery, she has remained free of disease 2.5 years after her initial
diagnosis of her cancer.
Conclusion
PNET of the ovary during pregnancy is a rare entity which requires
a multidisciplinary team approach to optimize both maternal onco-
logic outcomes and fetal well-being. Pros and cons of the treatment
options should be discussed with the patient in detail so as to allow
her to make an informed decision about the treatment plans. In a se-
lect group of young women with early stage cPNET of the ovary,
fertility-sparing treatment may be considered.
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